Longbow Finance SA Boosts Stake in Kenvue Inc. (NYSE:KVUE)

Longbow Finance SA boosted its stake in Kenvue Inc. (NYSE:KVUE) by 5.0% during the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 280,568 shares of the company’s stock after buying an additional 13,287 shares during the quarter. Longbow Finance SA’s holdings in Kenvue were worth $5,990,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the stock. Grove Bank & Trust lifted its stake in shares of Kenvue by 438.4% during the 4th quarter. Grove Bank & Trust now owns 1,163 shares of the company’s stock worth $25,000 after purchasing an additional 947 shares during the period. Geneos Wealth Management Inc. purchased a new position in shares of Kenvue during the 4th quarter worth $29,000. Fortitude Family Office LLC lifted its stake in shares of Kenvue by 106.6% during the 4th quarter. Fortitude Family Office LLC now owns 1,506 shares of the company’s stock worth $32,000 after purchasing an additional 777 shares during the period. Ashton Thomas Securities LLC acquired a new stake in shares of Kenvue during the 3rd quarter worth $35,000. Finally, Versant Capital Management Inc increased its holdings in shares of Kenvue by 300.8% during the 4th quarter. Versant Capital Management Inc now owns 1,920 shares of the company’s stock worth $41,000 after buying an additional 1,441 shares during the last quarter. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Wall Street Analyst Weigh In

KVUE has been the subject of several recent research reports. Royal Bank of Canada reiterated a “sector perform” rating and issued a $24.00 price target on shares of Kenvue in a report on Monday, February 3rd. Canaccord Genuity Group cut their target price on shares of Kenvue from $27.00 to $24.00 and set a “buy” rating on the stock in a report on Friday, February 7th. Piper Sandler raised their price objective on shares of Kenvue from $24.00 to $27.00 and gave the company an “overweight” rating in a research note on Monday. Citigroup lowered their price objective on shares of Kenvue from $25.00 to $21.00 and set a “neutral” rating on the stock in a research note on Wednesday, January 15th. Finally, UBS Group decreased their price target on shares of Kenvue from $23.00 to $21.00 and set a “neutral” rating on the stock in a research report on Friday, February 7th. One analyst has rated the stock with a sell rating, eight have given a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $23.08.

Kenvue Stock Up 0.0 %

Kenvue stock opened at $23.33 on Tuesday. The stock has a market capitalization of $44.72 billion, a PE ratio of 44.01, a price-to-earnings-growth ratio of 2.62 and a beta of 1.45. Kenvue Inc. has a twelve month low of $17.67 and a twelve month high of $24.46. The company has a quick ratio of 0.69, a current ratio of 1.00 and a debt-to-equity ratio of 0.66. The company has a 50 day moving average of $21.33 and a 200-day moving average of $22.21.

Kenvue (NYSE:KVUE) last announced its earnings results on Thursday, February 6th. The company reported $0.26 EPS for the quarter, hitting the consensus estimate of $0.26. Kenvue had a net margin of 6.66% and a return on equity of 20.97%. On average, equities research analysts anticipate that Kenvue Inc. will post 1.14 EPS for the current fiscal year.

Kenvue Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, February 26th. Stockholders of record on Wednesday, February 12th will be given a $0.205 dividend. This represents a $0.82 annualized dividend and a dividend yield of 3.52%. The ex-dividend date of this dividend is Wednesday, February 12th. Kenvue’s payout ratio is presently 154.72%.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.